Johnson & Johnson acquires Firefly Bio for $1 billion
Key takeaways
- Johnson & Johnson acquires Firefly Bio for $1 billion Quartz · Jeff Schear / Getty Images Colleen Cabili Mon, June 8, 2026 at 8:33 PM GMT+7 1 min read JNJ Johnson & Johnson agreed to acquire Firefly Bio, Inc.
- The platform targets tumors driven by a mutation in a gene known as KRAS, the company said.
- "We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors."
Johnson & Johnson acquires Firefly Bio for $1 billion Quartz · Jeff Schear / Getty Images Colleen Cabili Mon, June 8, 2026 at 8:33 PM GMT+7 1 min read JNJ Johnson & Johnson agreed to acquire Firefly Bio, Inc. for $1 billion in cash, the company said Monday, expanding its cancer drug pipeline with a platform designed to treat tumors that have resisted conventional therapies.
At the heart of the deal is Firefly's Firelink platform, which is designed to slip protein-degrading drugs inside cancer cells by hitching them to antibodies — a strategy intended to spare healthy tissue from the collateral damage typical of existing treatments, Reuters reported. The platform targets tumors driven by a mutation in a gene known as KRAS, the company said.
"KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years," said John Reed, executive vice president of innovative medicine, research and development at Johnson & Johnson, in a statement. "We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors."